VT103是一种选择性TEAD1蛋白棕榈酰化抑制剂。
Cas No.:2290608-13-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
VT103 is a selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD-mediated gene transcription, blocks TEAD auto-palmitoylation, and disrupts the interaction between YAP/TAZ and TEAD[1-2]. VT103 can be used in research related to HER2-positive breast cancer, prostate cancer, and triple-negative breast cancer[3-4].
In vitro, VT103 (10μM) was used to treat neonatal mouse cardiac fibroblasts (NMCFs) stimulated with angiotensin II (Ang-II; 100nM) for 48 hours. VT103 reversed the Ang-II-induced increase in α-SMA expression and inhibited collagen gel contraction and cell migration[5]. VT103 (10μM) was also used to treat human coronary artery smooth muscle cells (HCASMCs) overexpressing METTL14 for 24 hours. VT103 inhibited the expression of TEAD1, PDGFRB, CTGF, and Cyr61, restored the expression of contractile markers ACTA2, CNN1, and SM22α, and attenuated the METTL14 overexpression-enhanced cell viability, proliferation, and migration[6].
In vivo, VT103 (100mg/kg) combined with Dabrafenib (30mg/kg) was administered orally daily for 14 days to treat female BALB/c-nu mice bearing KTOR81 xenograft tumors. VT103 significantly inhibited tumor growth and maintained sustained tumor regression during a 42-day observation period, without significantly affecting mouse body weight[7]. VT103 (0.3, 1, 3mg/kg) was administered orally daily for 45 days to treat mice bearing NCI-H226 xenograft tumors. VT103 significantly inhibited tumor growth, and at the 3mg/kg dose, VT103 induced tumor regression without significantly affecting body weight during the treatment period[8].
References:
[1] Heinrich T, Peterson C, Schneider R, et al. Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106. J Med Chem. 2022 Jul 14;65(13):9206-9229.
[2] Vaparanta K, Song Z, Farahani I, et al. Phosphoproteomic analysis reveals the diversity of signaling behind ErbB-inhibitor-induced phenotypes. FEBS J. 2025 Dec;292(24):6557-6575.
[3] Zhang S, Tan YQ, Zhang X, et al. TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma. Oncogene. 2025 Mar;44(11):753-768.
[4] Evsen L, Morris PJ, Thomas CJ, et al. Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma. Pharmaceuticals (Basel). 2023 Nov 21;16(12):1635.
[5] Song S, Zhang X, Huang Z, et al. TEA domain transcription factor 1(TEAD1) induces cardiac fibroblasts cells remodeling through BRD4/Wnt4 pathway. Signal Transduct Target Ther. 2024 Feb 19;9(1):45.
[6] Wang L, Xia G, Tang Y, et al. METTL14 Promotes Vascular Smooth Muscle Cell Proliferation and Neointima Formation via m6A Methylation TEAD1 mRNA. J Biochem Mol Toxicol. 2025 May;39(5):e70284.
[7] Hosoya K, Ozasa H, Yoshida H, et al. Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation. Cancer Sci. 2025 Jul;116(7):1883-1896.
[8] Tang TT, Konradi AW, Feng Y, et al. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Mol Cancer Ther. 2021 Jun;20(6):986-998.
VT103是一种选择性TEAD1蛋白棕榈酰化抑制剂。VT103可抑制YAP/TAZ-TEAD促进的基因转录、阻断TEAD自棕榈酰化并破坏YAP/TAZ与TEAD之间的相互作用[1-2]。VT103可用于HER2阳性乳腺癌、前列腺癌和三阴性乳腺癌的相关研究[3-4]。
在体外，VT103（10μM）处理经血管紧张素II（Ang-II；100nM）刺激的新生小鼠心脏成纤维细胞（NMCFs）48小时。VT103可逆转Ang-II诱导的α-SMA表达增加，同时抑制胶原凝胶收缩和细胞迁移[5]。VT103（10μM）处理过表达METTL14的人冠状动脉平滑肌细胞（HCASMCs）24小时。VT103可抑制TEAD1、PDGFRB、CTGF、Cyr61表达，恢复收缩标志物ACTA2、CNN1、SM22α的表达，并减弱METTL14过表达所增强的细胞活力、增殖和迁移[6]。
在体内，VT103（100mg/kg）联合Dabrafenib（30mg/kg）每日口服给药，处理携带KTOR81异种移植瘤的雌性BALB/c-nu小鼠14天。VT103可显著抑制肿瘤生长，并在42天观察期内维持持续的肿瘤消退，同时未对小鼠体重产生显著影响[7]。VT103（0.3、1、3mg/kg）每日口服给药，用于处理携带NCI-H226异种移植瘤的小鼠45天。VT103显著抑制了肿瘤生长，在3mg/kg剂量下导致了肿瘤消退，同时治疗期间未对小鼠体重产生显著影响[8]。
| Cell experiment [1]: | |
Cell lines | Neonatal Mice Cardiac Fibroblasts (NMCFs) |
Preparation Method | Neonatal Mice Cardiac Fibroblasts (NMCFs) were stimulated with angiotensin II (Ang-II; 100nM). The cells were treated with VT103 (10μM) for 48 hours. |
Reaction Conditions | 10μM; 48h. |
Applications | VT103 reversed the Ang-II-induced increase in α-SMA expression. VT103 also inhibited collagen gel contraction and cell migration. |
| Animal experiment [2]: | |
Animal models | Six-week-old female BALB/c-nu mice |
Preparation Method | KTOR81 cells (5x10⁶) suspended in Matrigel were injected subcutaneously into the backs of the mice. Treatment was initiated when the tumor volume reached 200mm³. The mice was treated with VT103 (100mg/kg). |
Dosage form | 100mg/kg; p.o.; daily administration for 14 days. |
Applications | The combination of Dabrafenib and VT103 induced significant tumor shrinkage and showed a sustained response with maintained tumor regression during the 42 days observation period. The combination therapy did not cause significant adverse effects on the body weight of the mice. |
References: | |
| Cas No. | 2290608-13-6 | SDF | |
| 分子式 | C18H17F3N4O2S | 分子量 | 410.41 |
| 溶解度 | DMSO : 50 mg/mL (121.83 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4366 mL | 12.1829 mL | 24.3659 mL |
| 5 mM | 487.3 μL | 2.4366 mL | 4.8732 mL |
| 10 mM | 243.7 μL | 1.2183 mL | 2.4366 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet